Search results
ZymoGenetics, Inc was one of the oldest biotechnology/pharmaceutical companies in the USA, based in Seattle, Washington. The company was involved in the development of therapeutic proteins. Located on Lake Union, the address of the ZymoGenetics headquarters was 1201 Eastlake Avenue East.
ZYMO RESEARCH offers superior technologies and reliable NGS services for life science research. Explore their products and services for sample collection, DNA and RNA purification, epigenetics, microbiomics, and more.
Sep 8, 2010 · Bristol-Myers Squibb has struck a deal to buy Seattle-based ZymoGenetics for $885 million, snaring its development partner on a mid-stage hepatitis C program along with a pipeline that includes...
This fundamentally different strategy, sometimes called the “gene first” approach, is one on which a Seattle-based biotechnology company called ZymoGenetics has bet its future. Rather than creating and screening new chemical entities, ZymoGenetics plans to harness the therapeutic potential that exists inherently in specific categories of ...
Jan 13, 2009 · ZymoGenetics and Bristol-Myers Squibb struck a deal that could bring the Seattle company $1 billion or more if its product to treat hepatitis C reaches certain scientific, regulatory and ...
Oct 13, 2010 · ZymoGenetics is focused on the discovery, development, manufacture and commercialization of therapeutic proteins for the treatment of human disease. Thanks to a robust discovery program, promising drug pipeline and strong development capabilities, ZymoGenetics is an emerging leader among biotherapeutic companies.
Aug 25, 2010 · By. ZymoGenetics, Inc. (NASDAQ:ZGEN) today announced enrollment has been completed in the Phase 2b clinical trial with PEG-Interferon lambda and ribavirin in chronic hepatitis C virus (HCV) infection.
